19 May 2013
Keywords: Parkinsons, fipamezole, Santhera, Juvantia
Article | 17 August 2009
Swiss biotechnology firm Santhera Pharmaceuticals has entered into an agreement to gain rights to JP-1730/fipamezole from Finland-based Oy Juvantia ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 August 2009
17 May 2013
© 2013 thepharmaletter.com